HLB Life Science Co.,Ltd. completed the acquisition of 97.95% stake in LifeLiver Co, Ltd from a group of sellers.
March 20, 2018
Share
HLB Life Science Co.,Ltd. (KOSDAQ:A067630) agreed to acquire 97.95% stake in LifeLiver Co, Ltd from a group of sellers for KRW 79.5 billion on March 12, 2018. Under the terms of the transaction, HLB Life Science Co.,Ltd. will acquire 22.08 million shares. The consideration will be paid through issuance of 5th unregistered unguaranteed private convertible bonds for KRW 79.5 billion. The transaction was resolved by the Board of Directors of HLB Life Science Co.,Ltd. on March 12, 2018. The transaction is expected to close on March 21, 2018. Anse Accounting Corporation acted as an external rating institution in the transaction.
HLB Life Science Co.,Ltd. (KOSDAQ:A067630) completed the acquisition of 97.95% stake in LifeLiver Co, Ltd from a group of sellers on March 21, 2018. As a result of the transaction, HLB Life Science Co.,Ltd. became the largest shareholder of LifeLiver Co, Ltd.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
HLB LIFE SCIENCE CO., LTD. 
